REVIEW PAPER
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
Submission date: 2015-12-31
Final revision date: 2016-01-18
Acceptance date: 2016-01-22
Publication date: 2016-10-25
Cent Eur J Immunol 2016;41(3):311-316
KEYWORDS
ABSTRACT
Angiogenesis is a clue process for tissue development and function, both in normal and pathological conditions. This process is regulated by multiple molecular systems. One of the most potent is vascular endothelial growth factor (VEGF) and its receptor (VEGFR) system. Members of this family are involved in new vessel formation in embryogenesis and maturation, as well as in reparative or pathological reactions in later stages. They play a substantial role in regeneration, inflammation, wound healing, as well as in cancer pathology. Nowadays it is possible to modulate VEGF-VEGFR interactions in many pathological conditions using anti-VEGF therapy. This therapy has already achieved a grounded position in the management of rheumatological disorders, tumour progression, and metastasis. Such drugs as bevacizumab, ranibizumab, aflibercept, and pegaptanib have also proven to be very effective in the treatment of several ocular diseases, such as age-related macular degeneration (AMD), macular oedema, or proliferative retinopathies and iris neovascularisation. The indications for the application of this therapy in ophthalmology are becoming wider and wider. It may also be used for corneal pathologies and in anti-glaucoma procedures.
REFERENCES (65)
1.
Shibuya M (2014): VEGF-VEGFR signals in health and disease. Biomol Ther (Seoul) 22: 1-9.
2.
Van Bergen T, Vandewalle E, Van de Veire S, et al. (2011): The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res 93: 689-699.
3.
Shibuya M (2013): Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153: 13-19.
4.
Shibuya M (2011): Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2: 1097-1105.
5.
Tolentino M (2011): Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56: 95-113.
6.
Chalam KV, Brar VS, Murthy RK (2014): Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol 132: 1350-1354.
7.
Kaur C, Foulds WS, Ling EA (2008): Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2: 879-889.
8.
Kaur C, Sivakumar V, Foulds WS (2006): Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci 47: 1126-1141.
9.
Kim M, Lee C, Payne R, et al. (2015): Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Surv Ophthalmol 60: 524-535.
10.
Andreoli CM, Miller JW (2007): Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18: 502-508.
11.
Al-Latayfeh M, Silva PS, Sun JK, Aiello LP (2012): Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med 2: a006411.
12.
Popescu V, Pricopie S, Totir M, et al. (2015): Clinical use of Bevacizumab in treating refractory glaucoma. J Med Life 8: 8-12.
13.
Osaadon P, Fagan XJ, Lifshitz T, Levy J (2014): A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) 28: 510-520.
14.
Foxton RH, Finkelstein A, Vijay S, et al. (2013): VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol 182: 1379-1390.
15.
Noma H, Mimura T, Yasuda K, Shimura M (2014): Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma. Ophthalmologica 232: 102-109.
16.
Chang JH, Garg NK, Lunde E, et al. (2012): Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 57: 415-429.
17.
Zheng W, Aspelund A, Alitalo K (2014): Lymphangiogenic factors, mechanisms, and applications. J Clin Invest 124: 878-887.
18.
Daneshvar R (2013): Anti-VEGF agents and glaucoma filtering surgery. J Ophthalmic Vis Res 8: 182-186.
19.
Chen S, Zhou M, Wang W, et al. (2015): Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes. Acta Ophthalmol 93: e556-560.
20.
Aspelund A, Tammela T, Antila S, et al. (2014): The Schlemm’s canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. J Clin Invest 124: 3975-3986.
21.
Karpinich NO, Caron KM (2014): Schlemm’s canal: more than meets the eye, lymphatics in disguise. J Clin Invest 124: 3701-3703.
22.
Klein A, Loewenstein A (2016): Therapeutic monoclonal antibodies and fragments: Bevacizumab. Dev Ophthalmol 55: 232-245.
23.
Kimoto K, Kubota T (2012): Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol 2012: 852183.
24.
Park SC, Su D, Tello C (2012): Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther 12: 1641-1647.
25.
Horsley MB, Kahook MY (2010): Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 21: 112-117.
27.
SooHoo JR, Seibold LK, Kahook MY (2014): The link between intravitreal antivascular endothelial growth factor injections and glaucoma. Curr Opin Ophthalmol 25: 127-133.
28.
Ryu CL, Elfersy A, Desai U, et al. (2014): The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol 2014: 317694.
29.
Cardarelli WJ, Smith RA (2013): Managed care implications of age-related ocular conditions. Am J Manag Care 19 (5 Suppl): S85-91.
32.
Simha A, Braganza A, Abraham L, et al. (2013) Anti-vascular endothelial growth factor for neovascular glaucoma. Review Cochrane Database Syst Rev 10: CD007920.
33.
Akpek EK, Smith RA (2013): Current treatment strategies for age-related ocular conditions. Am J Manag Care 19 (5 Suppl): S76-84.
34.
Singh RS, Kim JE (2012): Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drugs Aging 29: 949-956.
35.
Bahar I, Yeung SN, Sella R, Slomovic A (2012): Anterior segment uses of bevacizumab. Curr Opin Ophthalmol 23: 303-316.
36.
Xiong Q, Li Z, Li Z, et al. (2014): Anti-VEGF agents with or without antimetabolites in trabeculectomy for glaucoma: a meta-analysis. PLoS One 9: e88403.
37.
Mansour AM, Shahin M, Kofoed PK, et al. (2012): Collaborative Anti-VEGF Ocular Vascular Complications Group. Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol 6: 343-363.
38.
SooHoo JR, Seibold LK, Kahook MY (2013): Recent advances in the management of neovascular glaucoma. Semin Ophthalmol 28: 165-172.
39.
Gismondi M, Salati C, Salvetat ML, et al. (2009): Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18: 658-661.
40.
Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008): Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146: 930-4.e1.
41.
Hollands H, Wong J, Bruen R, et al. (2007): Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42: 807-811.
42.
Aref AA (2012): Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol 23: 105-110.
43.
Kiddee W, Montriwet M (2015): Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents. PLoS One 10: e0137833.
44.
Cacciamani A, Oddone F, Parravano M, et al. (2013): Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 57: 63-67.
45.
Choi DY, Ortube MC, McCannel CA, et al. (2011): Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 31: 1028-1035.
46.
Good TJ, Kimura AE, Mandava N, Kahook MY (2011): Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95: 1111-1114.
47.
Dedania VS, Bakri SJ (2015): Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina 35: 841-858.
48.
Bakri SJ, Ekdawi NS (2008) Intravitreal silicone oil droplets after intravitreal drug injections. Retina 28: 996-1001.
49.
Kahook MY, Liu L, Ruzycki P, et al. (2010): High-molecular-weight aggregates in repackaged bevacizumab. Retina 30: 887-892.
50.
Sniegowski M, Mandava N, Kahook MY (2010): Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 4: 28-29.
51.
Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM (2008): Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246: 955-958.
52.
Kahook MY, Ammar DA (2010): In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 19: 437-441.
53.
Bakri SJ, Moshfeghi DM, Francom S, et al. (2014): Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 121: 1102-1108.
54.
Tseng JJ, Vance SK, Della Torre KE, et al. (2012): Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 21: 241-247.
55.
Hoang QV, Mendonca LS, Della Torre KE, et al. (2012): Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119: 321-326.
56.
Kim YJ, Sung KR, Lee KS, et al. (2014): Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol 157: 1266-1271.
57.
Kahook MY, Kimura AE, Wong LJ, et al. (2009): Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 40: 293-295.
58.
Skalicky SE, Ho I, Agar A, Bank A (2012): Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 43: 328-334.
59.
Sampat KM, Garg SJ (2010): Complications of intravitreal injections. Curr Opin Ophthalmol 21: 178-183.
60.
Bakri SJ, Larson TA, Edwards AO (2008): Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 246: 779-781.
61.
Higashide T, Murotani E, Saito Y, et al. (2012): Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 250: 603-610.
62.
Wilhelm A, Sietmann R, Wilhelm U, Hammer T (2015 ): The influence of VEGF inhibitors on corneal endothelium after injection into the anterior chamber in a porcine eye model. Ophthalmologe 112: 346-352.
63.
Rusovici R, Sakhalkar M, Chalam KV (2011): Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells. Mol Vis 17: 3339-3346.
64.
Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. (2008): Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81-87.
65.
Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T (2009): Cerebrovascular accidents in ranibizumab. Ophthalmology 116: 362.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
